

Imatinib toxicity criteria and severity descriptors

ULN = upper limit of normal

ADL = activities of daily living

Adverse event	Brief description of minimum grade	NIH common toxicity criteria grade
<i>Alimentary tract</i>		
Diarrhoea	Increase of more than 7 stools/day over pre-treatment or incontinence	3 (or higher)
Nausea	Inadequate oral intake requiring IV fluids	3 (or higher)
Vomiting	Six or more episodes in 24 hours over pre-treatment; IV fluids indicated	3 (or higher)
Weight gain	≥ 20% weight gain	3 (or higher)
<i>Cardiovascular/ fluid retention</i>		
Oedema	Symptomatic oedema limiting function and unresponsive to therapy or requiring drug discontinuation	3 (or higher)
Ascites	Symptomatic; requiring paracentesis	3 (or higher)
Pleural effusion	Symptomatic; requiring oxygen or thoracentesis	3 (or higher)
Pulmonary oedema	Symptomatic CHF responsive to treatment	3 (or higher)
<i>Central nervous system</i>		
Dizziness	Interfering with ADLs	3 (or higher)
Mood alteration - depression	Severe mood alteration interfering with activities of daily living	3 (or higher)
Fatigue	Severe fatigue interfering with ADL	3 (or higher)
<i>Dermatological</i>		
Rash/desquamation	Severe, generalised erythroderma or macular, papular or vesicular eruption; desquamation covering ≥ 50% body surface area	3 (or higher)
<i>Haematological</i>		

Gastrointestinal haemorrhage	Requiring transfusion	3 (or higher)
<i>Hepatic/ laboratory</i>		
Bilirubin	> 3 - 10 x ULN	3 (or higher)
Elevated transaminases	ALT and/or AST > 5 - 20 x ULN	3 (or higher)
Serum alkaline phosphatase	> 5 - 20 x ULN	3 (or higher)
Hypokalaemia	2.5 - < 3.0 mmol/L	3 (or higher)
<i>Respiratory</i>		
Cough (severe)	Severe cough or coughing spasm, poor control or unresponsive to treatment. Evidence of reversal on cessation of treatment	3 (or higher)
<i>Other</i>		
Fever (in the absence of neutropaenia)	Body temp > 40°C (oral or tympanic) for < 24 hours	3 (or higher)
Headaches (severe)	Severe pain (requiring compound analgesics) where pain or analgesics severely interfere with activities of daily living	3 (or higher)
Somatic pain (including joint pain, abdominal pain, musculoskeletal pain, cramp & myalgia)	Severe pain (requiring compound analgesics) where pain or analgesics severely interfere with activities of daily living	3 (or higher)